Literature DB >> 30228727

NASH: The Emerging Most Common Form of Chronic Liver Disease.

Meron Tesfay1, W Joseph Goldkamp2, Brent A Neuschwander-Tetri3.   

Abstract

Nonalcoholic steatohepatitis (NASH) is a common cause of chronic liver disease that can progress to cirrhosis and hepatocellular carcinoma. This review provides brief answers to common questions clinicians may have about NASH. The diagnosis of NASH currently requires a liver biopsy, although non-invasive tests are being evaluated and may supplant liver biopsy in the near future. Treatment is focused on lifestyle modifications, with new medications currently in clinical trials.

Entities:  

Mesh：

Year:  2018        PMID： 30228727      PMCID： PMC6140162     

Source DB:  PubMed          Journal:  Mo Med        ISSN： 0026-6620


  28 in total

1.  Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.

Authors:  David Goldberg; Ivo C Ditah; Kia Saeian; Mona Lalehzari; Andrew Aronsohn; Emmanuel C Gorospe; Michael Charlton
Journal:  Gastroenterology       Date:  2017-01-11       Impact factor: 22.682

Review 2.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

3.  Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.

Authors:  Kenneth Cusi; Beverly Orsak; Fernando Bril; Romina Lomonaco; Joan Hecht; Carolina Ortiz-Lopez; Fermin Tio; Jean Hardies; Celia Darland; Nicolas Musi; Amy Webb; Paola Portillo-Sanchez
Journal:  Ann Intern Med       Date:  2016-06-21       Impact factor: 25.391

Review 4.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.

Authors:  Parambir S Dulai; Siddharth Singh; Janki Patel; Meera Soni; Larry J Prokop; Zobair Younossi; Giada Sebastiani; Mattias Ekstedt; Hannes Hagstrom; Patrik Nasr; Per Stal; Vincent Wai-Sun Wong; Stergios Kechagias; Rolf Hultcrantz; Rohit Loomba
Journal:  Hepatology       Date:  2017-03-31       Impact factor: 17.425

5.  Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.

Authors:  Robert J Wong; Maria Aguilar; Ramsey Cheung; Ryan B Perumpail; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed
Journal:  Gastroenterology       Date:  2014-11-25       Impact factor: 22.682

6.  Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease.

Authors:  Sahil Mittal; Hashem B El-Serag; Yvonne H Sada; Fasiha Kanwal; Zhigang Duan; Sarah Temple; Sarah B May; Jennifer R Kramer; Peter A Richardson; Jessica A Davila
Journal:  Clin Gastroenterol Hepatol       Date:  2015-07-18       Impact factor: 11.382

7.  Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.

Authors:  Savino Bruno; Patrick Maisonneuve; Paola Castellana; Nicole Rotmensz; Sonia Rossi; Marco Maggioni; Marcello Persico; Alberto Colombo; Franco Monasterolo; Donata Casadei-Giunchi; Franco Desiderio; Tommaso Stroffolini; Virgilio Sacchini; Andrea Decensi; Umberto Veronesi
Journal:  BMJ       Date:  2005-03-03

8.  The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.

Authors:  Paul Angulo; Jason M Hui; Giulio Marchesini; Ellisabetta Bugianesi; Jacob George; Geoffrey C Farrell; Felicity Enders; Sushma Saksena; Alastair D Burt; John P Bida; Keith Lindor; Schuyler O Sanderson; Marco Lenzi; Leon A Adams; James Kench; Terry M Therneau; Christopher P Day
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

Review 9.  Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.

Authors:  Kathleen E Corey; Mary E Rinella
Journal:  Dig Dis Sci       Date:  2016-03-04       Impact factor: 3.199

Review 10.  Non-alcoholic fatty liver disease.

Authors:  Brent A Neuschwander-Tetri
Journal:  BMC Med       Date:  2017-02-28       Impact factor: 8.775
View more
  11 in total

Review 1.  Behavioral health disorders related to nonalcoholic steatohepatitis.

Authors:  Aadi Sharma; Somaya Albhaisi; Arun J Sanyal
Journal:  Clin Liver Dis (Hoboken)       Date:  2022-07-16

2.  Timely diagnosis and staging of non-alcoholic fatty liver disease using transient elastography and clinical parameters.

Authors:  Christine Shieh; Dina L Halegoua-De Marzio; Matthew L Hung; Jonathan M Fenkel; Steven K Herrine
Journal:  JGH Open       Date:  2020-06-29

3.  Serum coding and non-coding RNAs as biomarkers of NAFLD and fibrosis severity.

Authors:  Stefania Di Mauro; Alessandra Scamporrino; Salvatore Petta; Francesca Urbano; Agnese Filippello; Marco Ragusa; Maria T Di Martino; Francesca Scionti; Stefania Grimaudo; Rosaria M Pipitone; Graziella Privitera; Antonino Di Pino; Roberto Scicali; Luca Valenti; Paola Dongiovanni; Anna Fracanzani; Agata M Rabuazzo; Antonio Craxì; Michele Purrello; Francesco Purrello; Salvatore Piro
Journal:  Liver Int       Date:  2019-06-26       Impact factor: 5.828

4.  The asymmetric Pitx2 gene regulates gut muscular-lacteal development and protects against fatty liver disease.

Authors:  Shing Hu; Aparna Mahadevan; Isaac F Elysee; Joseph Choi; Nathan R Souchet; Gloria H Bae; Alessandra K Taboada; Bhargav Sanketi; Gerald E Duhamel; Carolyn S Sevier; Ge Tao; Natasza A Kurpios
Journal:  Cell Rep       Date:  2021-11-23       Impact factor: 9.423

5.  Diet-Induced Non-alcoholic Fatty Liver Disease and Associated Gut Dysbiosis Are Exacerbated by Oral Infection.

Authors:  Alexandra M Simas; Carolyn D Kramer; Caroline A Genco
Journal:  Front Oral Health       Date:  2022-01-24

Review 6.  Management of nonalcoholic fatty liver disease in the Middle East.

Authors:  Faisal M Sanai; Faisal Abaalkhail; Fuad Hasan; Muhammad Hamed Farooqi; Nawal Al Nahdi; Zobair M Younossi
Journal:  World J Gastroenterol       Date:  2020-07-07       Impact factor: 5.742

7.  ASC, IL-18 and Galectin-3 as Biomarkers of Non-Alcoholic Steatohepatitis: A Proof of Concept Study.

Authors:  Brianna Cyr; Robert W Keane; Juan Pablo de Rivero Vaccari
Journal:  Int J Mol Sci       Date:  2020-11-13       Impact factor: 5.923

Review 8.  Too Much of a Good Thing? An Evolutionary Theory to Explain the Role of Ceramides in NAFLD.

Authors:  Annelise M Poss; Scott A Summers
Journal:  Front Endocrinol (Lausanne)       Date:  2020-07-31       Impact factor: 5.555

9.  Partial Replacement of Dietary Fat with Krill Oil or Coconut Oil Alleviates Dyslipidemia by Partly Modulating Lipid Metabolism in Lipopolysaccharide-Injected Rats on a High-Fat Diet.

Authors:  Hee-Kyoung Son; Bok-Hee Kim; Jisu Lee; Seohyun Park; Chung-Bae Oh; Sunyoon Jung; Jennifer K Lee; Jung-Heun Ha
Journal:  Int J Environ Res Public Health       Date:  2022-01-12       Impact factor: 3.390

Review 10.  Unveiling the Role of the Fatty Acid Binding Protein 4 in the Metabolic-Associated Fatty Liver Disease.

Authors:  Juan Moreno-Vedia; Josefa Girona; Daiana Ibarretxe; Lluís Masana; Ricardo Rodríguez-Calvo
Journal:  Biomedicines       Date:  2022-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.